{"id":"placebo-eugonadal","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo eugonadal","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:29:29.249084+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:29:34.982220+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo eugonadal","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:29:35.318183+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo formulation, it contains no active pharmaceutical ingredient and serves as a control arm in clinical trials investigating gonadal hormone replacement or testosterone therapy. The term 'eugonadal' indicates the study population maintains normal gonadal function, allowing researchers to isolate the effects of active interventions from baseline hormonal status.","oneSentence":"Placebo eugonadal is an inert control substance used in clinical research to maintain normal testosterone levels as a comparator in hormone studies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:00:49.998Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:29:37.409221+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Control arm in clinical trials of testosterone replacement therapy or gonadal hormone studies"}]},"trialDetails":[{"nctId":"NCT00467987","phase":"NA","title":"Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism","status":"TERMINATED","sponsor":"University at Buffalo","startDate":"2007-06-01","conditions":"Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism","enrollment":47},{"nctId":"NCT01127659","phase":"PHASE4","title":"Testosterone Replacement in Men With Diabetes and Obesity","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2010-05","conditions":"Hypogonadism","enrollment":137},{"nctId":"NCT01155518","phase":"PHASE2","title":"Hypogonadism in Young Men With Type 2 Diabetes","status":"TERMINATED","sponsor":"State University of New York at Buffalo","startDate":"2010-06","conditions":"Hypogonadotropic Hypogonadism, Type 2 Diabetes","enrollment":5},{"nctId":"NCT01748370","phase":"PHASE4","title":"Vitamin D Treatment and Hypogonadism in Men","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2012-12-01","conditions":"Hypogonadism","enrollment":200},{"nctId":"NCT02366975","phase":"PHASE4","title":"TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST","status":"COMPLETED","sponsor":"University of Florence","startDate":"2012-11","conditions":"Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Hypogonadism","enrollment":143},{"nctId":"NCT01206400","phase":"","title":"Effect of Pioglitazone on Testosterone in Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2010-09","conditions":"Type 2 Diabetes Mellitus","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo eugonadal","genericName":"Placebo eugonadal","companyName":"Medical University of Graz","companyId":"medical-university-of-graz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo eugonadal is an inert control substance used in clinical research to maintain normal testosterone levels as a comparator in hormone studies. Used for Control arm in clinical trials of testosterone replacement therapy or gonadal hormone studies.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:29:37.409221+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}